目的探讨血清人附睾上皮分泌蛋白4(human epididymis protein 4,HE4)和CA125联合检测在卵巢癌诊断中的应用价值。方法将47例卵巢癌患者、42例卵巢良性疾病患者及56例健康对照者纳入本研究,检测术前患者血清HE4和CA125水平。结果卵巢癌患者血清HE4和CA125水平均明显高于卵巢良性疾病患者和健康对照者(P<0.01)。单项检测卵巢恶性肿瘤患者血清HE4、CA125及联合检测HE4和CA125的受试者工作特征曲线下面积ROC-AUC分别为0.904、0.881、0.914。卵巢恶性肿瘤组血清HE4单项检测的阳性率为74%,明显低于血清CA125单项榆测的阳性率(83%,P<0.001);联合检测HE4和CA125其阳性率为89%,高于单独检测HE4、CA125,差异有统计学意义(P<0.001)。结论血清HE4和CA125联合检测可以提高卵巢癌的诊断能力。 Objective To investigate the value of combined detection of serum human epididymis protein 4 (HE4) and CA125 in the diagnosis of ovarian cancer. Methods 47 patients with ovarian cancer, 42 patients with benign ovarian disease and 56 healthy controls were enrolled in this study. Preoperative serum HE4 and CA125 levels were measured. Results The levels of serum HE4 and CA125 in patients with ovarian cancer were significantly higher than those in patients with benign ovarian disease and healthy controls (P <0.01). The area under the working characteristic curve of subjects with single detection of serum HE4 and CA125 in patients with ovarian cancer and the combined detection of HE4 and CA125 were 0.904,0.881,0.914. The positive rate of HE4 single detection in ovarian malignant tumor group was 74%, which was significantly lower than that of serum CA125 (83%, P <0.001). The positive rate of HE4 and CA125 was 89% The detection of HE4, CA125, the difference was statistically significant (P <0.001). Conclusion Serum HE4 and CA125 combined detection can improve the diagnostic ability of ovarian cancer.